Michael F. Daily
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michael F. Daily has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Roberto Gedaly
Division of Transplantation, Department of Surgery, University of Kentucky, Lexington, KY
8 shared publications Jonathan Hundley
University of Kentucky College of Medicine Transplant Center Lexington KY USA
4 shared publicationsChangguo Chen
3 shared publications- Malay Bharat Shah
University of Kentucky, Lexington, KY, USA
3 shared publications Paul Angulo
3 shared publicationsB Mark Evers
2 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (10) , e70506
Pediatric Kidney Alone Versus Adult Simultaneous Kidney–Pancreas Recipients of Deceased Donor Kidneys: A Paired Analysis of 1675 Donors
Background: Allocation of high quality deceased donor kidneys to simultaneous pancreas–kidney (SPK) versus pediatric kidney alone (KI) recipients presents competing priorities regarding kidney allograft longevity and patient survival. We evaluated long‐term outcomes of contralateral kidneys transplanted into these distinct recipient populations to assess kidney allograft utility within this allocation framework. Methods: Using Scientific Registry of Transplant Recipients data from 2010–2025, we identified 1675 deceased donors whose kidneys were transplanted into an adult SPK recipient and a pediatric KI recipient. Outcomes included death censored graft survival (DCGS), patient survival, and freedom from composite graft failure or death. Kaplan–Meier analyses were performed with survival estimates at 1, 3, 5, and 10 years and log‐rank comparisons. Results: Ten‐year DCGS was significantly higher among adult SPK recipients than among pediatric KI recipients (82.1% versus 70.6%; p = 0.0001). Conversely, 10‐year patient survival was substantially higher among pediatric KI recipients (95.4% versus 78.3%; p = 0.0001). Despite these differences, 10‐year freedom from composite graft failure or death was comparable between SPK and pediatric KI recipients (69.1% versus 67.9%; p = 0.47). Conclusions: Among contralateral kidneys from the same deceased donors, adult SPK recipients demonstrated superior DCGS, whereas pediatric KI recipients experienced substantially better patient survival. Comparable long‐term composite outcomes highlight the competing considerations of graft longevity and recipient survival in deceased donor kidney allocation. These findings suggest that assessments of kidney allograft utility should consider both graft‐specific and recipient‐centered outcomes rather than relying on either endpoint independently.
- 22 October 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (10) , e70506
Open AccessPediatric Kidney Alone Versus Adult Simultaneous Kidney–Pancreas Recipients of Deceased Donor Kidneys: A Paired Analysis of 1675 Donors
Background: Allocation of high quality deceased donor kidneys to simultaneous pancreas–kidney (SPK) versus pediatric kidney alone (KI) recipients presents competing priorities regarding kidney allograft longevity and patient survival. We evaluated long‐term outcomes of contralateral kidneys transplanted into these distinct recipient populations to assess kidney allograft utility within this allocation framework. Methods: Using Scientific Registry of Transplant Recipients data from 2010–2025, we identified 1675 deceased donors whose kidneys were transplanted into an adult SPK recipient and a pediatric KI recipient. Outcomes included death censored graft survival (DCGS), patient survival, and freedom from composite graft failure or death. Kaplan–Meier analyses were performed with survival estimates at 1, 3, 5, and 10 years and log‐rank comparisons. Results: Ten‐year DCGS was significantly higher among adult SPK recipients than among pediatric KI recipients (82.1% versus 70.6%; p = 0.0001). Conversely, 10‐year patient survival was substantially higher among pediatric KI recipients (95.4% versus 78.3%; p = 0.0001). Despite these differences, 10‐year freedom from composite graft failure or death was comparable between SPK and pediatric KI recipients (69.1% versus 67.9%; p = 0.47). Conclusions: Among contralateral kidneys from the same deceased donors, adult SPK recipients demonstrated superior DCGS, whereas pediatric KI recipients experienced substantially better patient survival. Comparable long‐term composite outcomes highlight the competing considerations of graft longevity and recipient survival in deceased donor kidney allocation. These findings suggest that assessments of kidney allograft utility should consider both graft‐specific and recipient‐centered outcomes rather than relying on either endpoint independently.
- 1 January 2018
- Published by Elsevier in Journal of Surgical Research
- Vol. 221, 88-94
Socioeconomic factors as predictors of organ donation
- 1 January 2018
- Published by Elsevier in Journal of Surgical Research
- Vol. 221, 88-94
Socioeconomic factors as predictors of organ donation
- 19 January 2016
- Published by Wiley in Liver International
- Vol. 36 (7) , 1018-1025
Combined liver–kidney transplantation for polycystic liver and kidney disease: analysis from the United Network for Organ Sharing dataset
Background & Aims: The purpose of this study was to evaluate predictors of outcomes in combined liver–kidney transplants for polycystic liver and kidney disease.Methods: We queried the United Network for Organ Sharing dataset for combined liver–kidney transplants performed from 1988 to 2013.Results: Out of 107 patients who had combined liver–kidney transplants for polycystic liver and kidney disease, 84 were women (78.5%) with a mean age of 54.9 ±7.2 years. Kaplan–Meier analysis demonstrated that patients undergoing liver–kidney transplantation for polycystic liver and kidney disease had better survival than patients with polycystic liver disease undergoing liver transplant alone and those undergoing liver–kidney transplantation for other indications. This group had a 1‐, 3‐ and 5‐year survival of 91%, 90% and 90%, respectively. Multivariable analysis demonstrated that an indication of polycystic liver and kidney disease for combined liver–kidney transplant (hazard ratio, 0.29; 95% confidence interval, 0.129–0.526; P < 0.001) and Model for End‐Stage Liver Disease score (hazard ratio, 1.271; 95% confidence interval, 1.093–1.477; P = 0.002) are independently associated with patient survival. In a propensity score analysis adjusting for age, gender, cold ischaemia time and total bilirubin and excluding hepatitis C, we found that patients transplanted with combined liver–kidney for other indications have similar survival compared with our study group.Conclusions: Combined liver–kidney transplantation for polycystic liver and kidney disease can achieve good outcomes in selected patients. On Cox regression analysis, patients with polycystic liver and kidney disease undergoing liver–kidney transplantation had better survival compared with patients with combined liver–kidney for other indications. After excluding hepatitis C patients, those transplanted for polycystic liver and kidney disease vs other indications had similar survival after combined liver–kidney transplantation. Interestingly, patients in the combined polycystic liver and kidney disease group have significantly better outcomes than patients with polycystic liver disease undergoing liver transplant alone.
- 19 January 2016
- Published by Wiley in Liver International
- Vol. 36 (7) , 1018-1025
Combined liver–kidney transplantation for polycystic liver and kidney disease: analysis from the United Network for Organ Sharing dataset
Background & Aims: The purpose of this study was to evaluate predictors of outcomes in combined liver–kidney transplants for polycystic liver and kidney disease.Methods: We queried the United Network for Organ Sharing dataset for combined liver–kidney transplants performed from 1988 to 2013.Results: Out of 107 patients who had combined liver–kidney transplants for polycystic liver and kidney disease, 84 were women (78.5%) with a mean age of 54.9 ±7.2 years. Kaplan–Meier analysis demonstrated that patients undergoing liver–kidney transplantation for polycystic liver and kidney disease had better survival than patients with polycystic liver disease undergoing liver transplant alone and those undergoing liver–kidney transplantation for other indications. This group had a 1‐, 3‐ and 5‐year survival of 91%, 90% and 90%, respectively. Multivariable analysis demonstrated that an indication of polycystic liver and kidney disease for combined liver–kidney transplant (hazard ratio, 0.29; 95% confidence interval, 0.129–0.526; P < 0.001) and Model for End‐Stage Liver Disease score (hazard ratio, 1.271; 95% confidence interval, 1.093–1.477; P = 0.002) are independently associated with patient survival. In a propensity score analysis adjusting for age, gender, cold ischaemia time and total bilirubin and excluding hepatitis C, we found that patients transplanted with combined liver–kidney for other indications have similar survival compared with our study group.Conclusions: Combined liver–kidney transplantation for polycystic liver and kidney disease can achieve good outcomes in selected patients. On Cox regression analysis, patients with polycystic liver and kidney disease undergoing liver–kidney transplantation had better survival compared with patients with combined liver–kidney for other indications. After excluding hepatitis C patients, those transplanted for polycystic liver and kidney disease vs other indications had similar survival after combined liver–kidney transplantation. Interestingly, patients in the combined polycystic liver and kidney disease group have significantly better outcomes than patients with polycystic liver disease undergoing liver transplant alone.
- 1 April 2015
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 150 (4) , 337-42
Role of Transplantation in the Treatment of Benign Solid Tumors of the Liver
Research from JAMA Surgery — Role of Transplantation in the Treatment of Benign Solid Tumors of the Liver — A Review of the United Network of Organ Sharing Data Set
- 1 April 2015
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 150 (4) , 337-42
Role of Transplantation in the Treatment of Benign Solid Tumors of the Liver
Research from JAMA Surgery — Role of Transplantation in the Treatment of Benign Solid Tumors of the Liver — A Review of the United Network of Organ Sharing Data Set
- 1 August 2012
- Published by Elsevier in Journal of Surgical Research
- Vol. 176 (2) , 542-548
PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation
- 1 August 2012
- Published by Elsevier in Journal of Surgical Research
- Vol. 176 (2) , 542-548
PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation
- 1 July 2012
- Vol. 32 (7) , 2531-6
The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Deregulated RAS/RAF/MAPK and PI3K/AKT/mTOR signaling pathways are found in hepatocellular carcinoma (HCC). This study aimed to test the inhibitory effects of PI-103 (a small molecule inhibitor of PI3K and mTOR) and sorafenib as single agents and in combination on HCC tumorigenesis in an in vivo xenograft model. In vitro study: Huh7 proliferation was assayed by 3H-thymidine incorporation and by thiazolyl blue tetrazolium bromide (MTT) assay. Western blots were used to detect phosphorylation of the key enzymes in the two pathways. In vivo study: Human HCC cell line Huh7 was inoculated into nude mice s.c. and the mice were treated with sorafenib (20 mg/kg/day) and PI-103 (5 mg/kg, every 4 days). Tumor size was measured every other day. Tumors were isolated for western blot and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay detection of apoptosis and signaling pathway enzymes. Our in vitro study found that combination of sorafenib and PI-103 additively inhibited Huh7 proliferation as compared to single-agent treatment. Sorafenib and PI-103 as single agents differentially inhibited or activated key enzymes (MEK, ERK, AKT, mTOR, and S6K) in PI3K/AKT/mTOR and RAS/RAF/MAPK signaling pathways. Combination of sorafenib and PI-103 inhibited all the key enzymes in the two pathways. Our in vivo study demonstrated significant differences between control group, mono-drug groups and drug-combination group (p<0.05). Combination of Sorafenib and PI-103 more efficiently inhibited tumorigenesis as compared to mono-drug treatments (p<0.032). The combination of PI-103 and sorafenib has the advantage over mono-drug therapy on inhibition of HCC cell proliferation and tumorigenesis by inhibiting both PI3K/AKT/mTOR and RAS/RAF/MAPK signaling pathways.
- 1 July 2012
- Vol. 32 (7) , 2531-6
The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Deregulated RAS/RAF/MAPK and PI3K/AKT/mTOR signaling pathways are found in hepatocellular carcinoma (HCC). This study aimed to test the inhibitory effects of PI-103 (a small molecule inhibitor of PI3K and mTOR) and sorafenib as single agents and in combination on HCC tumorigenesis in an in vivo xenograft model. In vitro study: Huh7 proliferation was assayed by 3H-thymidine incorporation and by thiazolyl blue tetrazolium bromide (MTT) assay. Western blots were used to detect phosphorylation of the key enzymes in the two pathways. In vivo study: Human HCC cell line Huh7 was inoculated into nude mice s.c. and the mice were treated with sorafenib (20 mg/kg/day) and PI-103 (5 mg/kg, every 4 days). Tumor size was measured every other day. Tumors were isolated for western blot and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay detection of apoptosis and signaling pathway enzymes. Our in vitro study found that combination of sorafenib and PI-103 additively inhibited Huh7 proliferation as compared to single-agent treatment. Sorafenib and PI-103 as single agents differentially inhibited or activated key enzymes (MEK, ERK, AKT, mTOR, and S6K) in PI3K/AKT/mTOR and RAS/RAF/MAPK signaling pathways. Combination of sorafenib and PI-103 inhibited all the key enzymes in the two pathways. Our in vivo study demonstrated significant differences between control group, mono-drug groups and drug-combination group (p<0.05). Combination of Sorafenib and PI-103 more efficiently inhibited tumorigenesis as compared to mono-drug treatments (p<0.032). The combination of PI-103 and sorafenib has the advantage over mono-drug therapy on inhibition of HCC cell proliferation and tumorigenesis by inhibiting both PI3K/AKT/mTOR and RAS/RAF/MAPK signaling pathways.
- Open Access
- 14 April 2012
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 18 (8) , 993-994
Thrombectomy and cavocavostomy for inferior vena cava thrombosis and torsion after piggyback liver transplantation
- 14 April 2012
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 18 (8) , 993-994
Open AccessThrombectomy and cavocavostomy for inferior vena cava thrombosis and torsion after piggyback liver transplantation
- 1 December 2010
- Vol. 30 (12) , 4951-8
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Aberrant Ras/Raf/MAPK and PI3K/AKT/mTOR signaling pathways are found in hepatocellular carcinoma (HCC). This study reports how sorafenib (a multi-kinase inhibitor) and PI-103 (a dual PI3K/mTOR inhibitor) alone and in combination inhibit the proliferation of the HCC cell line, Huh7. Huh7 proliferation was assayed by 3H-thymidine incorporation and by MTT assay. Western blot was used to detect phosphorylation of the key enzymes in the Ras/Raf and PI3K pathways. Sorafenib and PI-103, as single agents inhibited Huh7 proliferation and epidermal growth factor (EGF)-stimulated Huh7 proliferation in a dose-dependent fashion; the combination of sorafenib and PI-103 produced synergistic effects. EGF increased phosphorylation of MEK and ERK, key Ras/Raf downstream signaling proteins; this activation was inhibited by sorafenib. However, sorafenib as a single agent increased AKT(Ser473) and mTOR phosphorylation. EGF-stimulated activation of PI3K/AKT/mTOR pathway components was inhibited by PI-103. PI-103 is a potent inhibitor of AKT(Ser473) phosphorylation; in contrast, rapamycin stimulated AKT(Ser473) phosphorylation. It was found that PI-103, as a single agent, stimulated MEK and ERK phosphorylation. However, the combination of sorafenib and PI-103 caused inhibition of all the tested kinases in the Ras/Raf and PI3K pathways. The combination of sorafenib and PI-103 can significantly inhibit EGF-stimulated Huh7 proliferation by blocking both Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
- 1 December 2010
- Vol. 30 (12) , 4951-8
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Aberrant Ras/Raf/MAPK and PI3K/AKT/mTOR signaling pathways are found in hepatocellular carcinoma (HCC). This study reports how sorafenib (a multi-kinase inhibitor) and PI-103 (a dual PI3K/mTOR inhibitor) alone and in combination inhibit the proliferation of the HCC cell line, Huh7. Huh7 proliferation was assayed by 3H-thymidine incorporation and by MTT assay. Western blot was used to detect phosphorylation of the key enzymes in the Ras/Raf and PI3K pathways. Sorafenib and PI-103, as single agents inhibited Huh7 proliferation and epidermal growth factor (EGF)-stimulated Huh7 proliferation in a dose-dependent fashion; the combination of sorafenib and PI-103 produced synergistic effects. EGF increased phosphorylation of MEK and ERK, key Ras/Raf downstream signaling proteins; this activation was inhibited by sorafenib. However, sorafenib as a single agent increased AKT(Ser473) and mTOR phosphorylation. EGF-stimulated activation of PI3K/AKT/mTOR pathway components was inhibited by PI-103. PI-103 is a potent inhibitor of AKT(Ser473) phosphorylation; in contrast, rapamycin stimulated AKT(Ser473) phosphorylation. It was found that PI-103, as a single agent, stimulated MEK and ERK phosphorylation. However, the combination of sorafenib and PI-103 caused inhibition of all the tested kinases in the Ras/Raf and PI3K pathways. The combination of sorafenib and PI-103 can significantly inhibit EGF-stimulated Huh7 proliferation by blocking both Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.